Company intelligence / Profile preview

LENZ Therapeutics

Solana Beach, California, United Stateslenz-tx.com ↗

Ownership: Public · LENZ
Development stage: NDA

Overview

LENZ Therapeutics has completed pivotal Phase 3 CLARITY trials for its lead candidate LNZ100 and submitted a New Drug Application to the FDA for presbyopia treatment. The product demonstrated improvement in near vision without compromising distance vision. Commercial launch activities are planned to begin immediately upon potential approval in Q4 2025.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (aceclidine-based ophthalmic solutions)
Industry: Biotech

Drug pipeline

2 assets

aceclidine

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of May 2025.

Financials

Market cap: $167.1M
Total revenue: $5.5M
Enterprise value: $-52.8M

Beyond the preview

Go deeper on LENZ Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LENZ Therapeutics.

Explore the full profile